Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Transforming Hemophilia A Treatment with Bispecific Antibodies – NEJM Group
NEJM Group/LinkedIn
Sep 14, 2026, 06:55

Transforming Hemophilia A Treatment with Bispecific Antibodies – NEJM Group

NEJM Group shared a post on LinkedIn about a recent article by Flora Peyvandi, published in The New England Journal of Medicine, adding;

“Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker-DeBakey Clinical Medical Research Award.

For decades, the treatment of hemophilia A rested on a single principle: replacing factor VIII, the missing clotting factor.

Plasma-derived and recombinant factor VIII concentrates transformed a once-fatal disease into a manageable chronic condition through prophylaxis and treatment.

But factor VIII has a relatively short half-life and thus is administered through frequent intravenous infusions, and neutralizing anti-factor VIII antibodies (inhibitors) that render replacement therapy ineffective develop in up to one third of patients with severe hemophilia A.

By showing that the coagulation cascade could be activated in the absence of factor VIII, Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa (of Chugai Pharmaceutical) overcame these limitations.

They developed a bispecific antibody that mimics blood coagulation factor VIlI, an achievement recognized by the 2026 Lasker-DeBakey Clinical Medical Research Award.”

Title: Reengineering Coagulation with a Bispecific Antibody

Authors: Flora PeyvandiTransforming Hemophilia A Treatment with Bispecific Antibodies - NEJM Group

Stay updated on all scientific advances with Hemostasis Today.

 

bispecific antibody bleeding disorders Chugai Pharmaceutical Clinical Research coagulation Emicizumab Factor VIII Factor VIII Inhibitors Flora Peyvandi Hematology Hemophilia A Hemophilia Treatment Hemostasis Lasker Award Lasker-DeBakey Clinical Medical Research Award NEJM Group Prophylaxis therapeutic innovation
NewsFeed